The minimal residual disease testing market involves quantification and detection of residual disease or malignant cells in cancer patients who have undergone treatment. Minimal residual disease testing finds the presence of malignant cancer cells that cannot be detected by conventional clinical and imaging techniques after cancer treatment. It helps monitor cancer and allows doctors to determine whether the treatment was effective or if additional therapy is needed.
The global minimal residual disease testing market is estimated to be valued at US$ 2.31 Bn in 2024 and is expected to exhibit a CAGR of 11% over the forecast period 2024 To 2031.
Key Takeaways
Key players operating in the minimal residual disease testing are Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche Ltd, Guardant Health, Inc., Adaptive Biotechnologies, Invitae Corporation, ASURAGEN, INC., Invivoscribe, Inc., Laboratory Corporation of America Holdings, Natera, Inc., Sysmex Inostics, Inc., Amgen Inc., FOUNDATION MEDICINE, INC., Sebia, and Myriad Genetics, Inc. The major key players are focusing on launching advanced MRD testing platforms and solutions. For instance, in September 2019, Adaptive Biotechnologies launched clonoSEQ Assay for minimal residual disease (MRD) testing in acute lymphoblastic leukemia and multiple myeloma.
The key opportunities in the minimal residual disease testing market are increasing applications of Minimal Residual Disease Testing Market Demand across different cancer types. MRD testing is increasingly recommended for hematologic cancers such as leukemia, lymphoma, and multiple myelomas. Additionally, growing adoption of precision medicine is also creating new opportunities as MRD assays are increasingly being used for monitoring targeted cancer therapies.
Globally, the minimal residual disease testing market is expanding due to increasing cancer prevalence worldwide coupled with rising healthcare expenditure. Additionally, growing awareness regarding early cancer detection and monitoring is supporting the demand of MRD testing. The market players are also expanding their geographical presence across emerging markets of Asia Pacific and Latin America owing to increasing incidences of cancer and healthcare infrastructure development.
Market Drivers:
The rising prevalence of cancer worldwide is a major market driver. According to WHO, cancer burden has risen to 19.3 million new cases and 10 million cancer deaths in 2020. MRD testing aids in monitoring treatment effectiveness and relapse risk.
Growing preference for non-invasive diagnostic techniques is another key factor augmenting demand. MRD testing utilizes blood or bone marrow samples for detection as opposed to surgical tissue biopsies, making it more convenient and less painful option.
Market Restraints:
Technological challenges remain in improving sensitivity and reliability of MRD assays. False negative results can downplay the actual disease burden and failure to detect low levels of residual cells. This restrains complete reliance on MRD testing.
Segment Analysis
The minimal residual disease testing market is segmented based on product and services which includes instruments, reagents and kits, and software and services. Among this, the reagent and kits segment is dominating the market owing to high usage of reagents and kits in MRD testing procedures. Reagents and kits are essential components to perform MRD testing using molecular techniques such as flow cytometry, polymerase chain reaction (PCR), and next generation sequencing (NGS). These reagents and kits help detect very low levels of residual disease that cannot be detected using conventional pathological techniques.
Global Analysis
Regionally, North America is expected to dominate the minimal residual disease testing market during the forecast period. This is due to increasing prevalence of hematological cancers and solid tumors along with rising healthcare expenditure. Also, presence of major players, quick adoption of advanced technologies and government support for R&D activities are some of the major factors driving the MRD testing market in North America. Asia Pacific is expected to witness highest growth during the forecast period due to rising awareness, improving healthcare infrastructure and increasing healthcare spending in emerging economies like India and China.
Get more insights on This Topic- Minimal Residual Disease Testing Market